Last reviewed · How we verify
IVMP
At a glance
| Generic name | IVMP |
|---|---|
| Also known as | methylprednisolone, prednisolone |
| Sponsor | Feng Jinzhou |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study (PHASE4)
- Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder (PHASE4)
- Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder (PHASE2)
- Efficacy and Safety of Monoclonal Antibody in Acute Phase of Neuromyelitis Optica Spectrum Disorder
- Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder (PHASE2)
- CPI Combination Therapy for Autoimmune Encephalitis (NA)
- Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders
- FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IVMP CI brief — competitive landscape report
- IVMP updates RSS · CI watch RSS
- Feng Jinzhou portfolio CI